The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease

BACKGROUND: Sodium–glucose cotransporter 2 (SGLT2) inhibitors are an antihyperglycemic drug with diuretic action. We recently reported that the SGLT2 inhibitor dapagliflozin ameliorates extracellular volume expansion with a mild increase in urine volume. However, the impact of the pretreatment extra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Diabetol Metab Syndr
Autores principales: Ohara, Ken, Masuda, Takahiro, Morinari, Masato, Okada, Mari, Miki, Atsushi, Nakagawa, Saki, Murakami, Takuya, Oka, Kentaro, Asakura, Maki, Miyazawa, Yasuharu, Maeshima, Akito, Akimoto, Tetsu, Saito, Osamu, Nagata, Daisuke
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7195732/
https://ncbi.nlm.nih.gov/pubmed/32377235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-020-00545-z
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares